

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

**Draft Guidance on Aprocitentan**

**November 2025**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

---

**Active Ingredient:** Aprocitentan

**Dosage Form:** Tablet

**Route:** Oral

**Strength:** 12.5 mg

**Recommended Study:** One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting

Design: Single-dose, two-treatment, two-period crossover in vivo

Strength: 12.5 mg

Subjects: Healthy males and non-pregnant, non-lactating females

Additional comments:

- Exclude geriatric subjects due to increased risk of fluid retention. Exclude subjects with abnormal complete blood counts or liver function tests. Females of reproductive potential should use effective contraception during the study and for one month after the last dose.
- Ensure an adequate washout period between treatments in the crossover study due to the long elimination half-life of aprocitentan. Alternatively, a parallel study design may be considered.

**Analyte to measure:** Aprocitentan in plasma

**Bioequivalence based on (90% CI):** Aprocitentan

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units for each of the test product and reference listed drug (RLD).<sup>1</sup> Specifications will be determined upon review of the abbreviated new drug application.

---

**Document History:** Recommended November 2025

**Unique Agency Identifier:** PSG\_217686

---

<sup>1</sup> If the RLD is not available, refer to the most recent version of the guidance for industry *Referencing Approved Drug Products in ANDA Submissions*.